Posts Tagged ‘patient outcomes’
Clinical trials are a vital part of medical testing, and their results determine treatment options for those diagnosed with an array of diseases. For those with mesothelioma, a deadly cancer caused by exposure to asbestos that affects the lining of the heart, lungs or abdomen, the results of clinical trials can determine how much longer a patient has to live.
A new study published in the journal The Oncologist stresses the important differences between two ways clinical trials determine outcomes for mesothelioma patients, according to Mesothelioma Research News. (more…)
Mesothelioma Research News reports drug 5-aza-dC has been found in a recent study to reduce DNA methylation, a common gene “signaling tool that locks the genes in the ‘off’ position,” according to Nature Education, and could possibly “improve the effectiveness of anti-cancer drugs and reduce the most aggressive mesothelioma cells that are often associated with treatment resistance.” (more…)
FASL gene along with platinum-based chemo could allow doctors to predict how long mesothelioma takes to progress, study says5 Jan 2017 by Sarah Mahan under Research/Treatment
For geneticists, the key to a person’s future is found on the microbiological level, and a recent Egyptian study has harnessed that insight to determine if certain genes can help predict mesothelioma patient outcomes.
Though multimodal treatment, including a combination of surgery, chemotherapy and radiation, can significantly improve a mesothelioma patient’s survival time, most diagnoses occur at later stages, when it is far too late for surgery and the talk turns to treatment options and how long a patient has to live.
Researchers in a new Egyptian study believe they have found a gene — FASL-844 CC — that can help predict how long a patient with mesothelioma can survive without disease progression, according to Mesothelioma Research News. (more…)